JKT:KLBF
PT Kalbe Farma Tbk. · JKT · Healthcare · IDR · FY for 2025
Figures on this page computed 2026-11-08 13:29 UTC
Last close
n/aIDR
Market data
9.4xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- IDR
- computed
- Computed from the filing for 2025
18.5%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
10.4%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
7.0%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
0.01Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- IDR
- Computed from the filing for 2025
- Computed from the filing for 2025
4.8%Dividend yield
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- IDR
- computed
6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
Follow one rupiah
lens 1 of 9After what it costs to make
39.8%
After running the business
12.9%
After interest and tax
10.4%
After what it must reinvest
7.0%
Kept after the dividend
2.3%
The five stops
5 of 5 read- After what it costs to make14,055,520,000,00039.8%
- After running the business4,545,017,000,00012.9%
- After interest and tax3,664,998,000,00010.4%
- After what it must reinvest2,460,783,000,0007.0%
- Kept after the dividend824,981,000,0002.3%
Of every unit of sales, 0.02 is still there after the dividend.
Of every unit of sales, 0.02 is still there after the dividend.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2025
Sales35,324,544,000,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- IDR
After what it costs to make14,055,520,000,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- IDR
After running the business4,545,017,000,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- IDR
After interest and tax3,664,998,000,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- IDR
After what it must reinvest2,460,783,000,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- IDR
Kept after the dividend824,981,000,000
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- IDR